We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Precision
Our proprietary chRDNA (CRISPR hybrid RNA-DNA) technology enables improved genome-editing specificity at high efficiency, and we are applying chRDNA to develop sophisticated genome-edited cell therapies.

Allogeneic
Building upon the early successes of autologous cell therapies, we are developing next-generation allogeneic CAR-T and CAR-NK cell therapies with significant potential to address the limitations of patient-derived treatments.

Persistence
We believe persistence is the key to developing successful allogeneic cell therapies. We use our proprietary technologies to enhance persistence by preventing rejection or rapid exhaustion of our cell therapies.

Caribou Biosciences, Inc. Memberships

Contact supplier